Zomedica Pharmaceuticals Corp.

Zomedica Pharmaceuticals Corp.

Zomedica Pharmaceuticals Corp. was founded to serve the veterinary market, though the exact founding year is not disclosed. CEO Larry Heaton leads the company alongside an executive team that includes Tony Blair as COO and Karen DeHaan-Fullerton as General Counsel. The firm has not publicly disclosed a wealth-origin or family-office structure; given its public listing, it operates as a corporate entity rather than a family office. Zomedica focuses on providing products that streamline veterinary workflows and enhance patient care. Its portfolio spans diagnostic technology (TRUFORMA), targeted pulsed electromagnetic field therapy (Assisi), shock wave therapy (PulseVet), and a rapid hemostatic gel (VETIGEL). The firm serves the US market and has international sales via Paul Tye. It does not publicly disclose AUM, deployment figures, or an investment mandate with traditional asset classes. As a publicly traded company, Zomedica reports to shareholders and maintains a board of directors chaired by Jeff Rowe. The firm employs professionals including vice presidents across R&D, technology innovation, imaging, and human resources. No additional offices, philanthropic foundations, or investment vehicles are disclosed. The company has not reported a major operational event in the last 24 months. Zomedica's structural differentiator is its purely operational focus on veterinary products, not capital allocation. As a public company, it lacks the private-wealth architecture typical of family offices. Its governance follows corporate norms with a board and SEC reporting posture.